VKTX 241206 46.50C (VKTX241206C46500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

VKTX241206C46500

Watchlist

5.10
-4.50-46.88%

15min DelayClose Dec 2 16:00 ET

5.10High5.10Low

Intraday

5D
Daily

News

Corbus, Viking Initiated at Overweight by Piper Sandler
Seeking Alpha13:34 ET
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
BenzingaDec 2 08:56 ET
Piper Sandler Initiates Coverage On Viking Therapeutics With Overweight Rating, Announces Price Target of $74
BenzingaDec 2 05:48 ET · Ratings
Piper Sandler Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $74
Moomoo NewsDec 2 05:34 ET · Ratings
Express News | Viking Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $74
ReutersDec 2 04:16 ET
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
BenzingaNov 29 08:42 ET

Comments

Shaaaw

Nov 27 06:52

Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...